EDIT Stock Jumps on EDIT-401 CRISPR Data: Is Editas Medicine Becoming an In Vivo Gene Editing Comeback Play?
Key Takeaways Editas Medicine (NASDAQ: EDIT) moved sharply higher as investors focused on the company’s EDIT-401 program, recent preclinical data, and renewed interest in CRISPR gene editing stocks. EDIT-401 is Editas Medicine’s lead in vivo gene editing candidate for hyperlipidemia and atherosclerotic cardiovascular disease risk reduction. The company reported strong non-human primate data showing roughly … Read more